Organon announced that CEO Kevin Ali intends to resign from his position following results from an internal investigation ...

In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research suggesting Ozempic may reduce biological age, and Novartis’ $12 billion ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Novartis will acquire Avidity Biosciences in a newly announced definitive merger agreement. The news follows the separation ...

PE: What makes TrumpRx different from other government-run health programs? O’Dell: TrumpRx is different in that its ...

Obesity is a complex, treatable medical condition, not just a matter of willpower, requiring a shift in perception and ...

Biologic age is determined by measuring how well the body’s cells and organs are functioning. This is different than ...

Two decades ago, manufacturers launched patient support services to counter a distorted pharmaceutical supply chain - one designed for intermediaries, not patients, that shifts complexity and cost ...

Lynkuet is the first dual neurokinin receptor antagonist approved for moderate to severe VMS in menopause, offering a hormone-free treatment option. Phase III OASIS trials showed significant ...

In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug ...

GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...

Eli Lilly and Company announced a definitive agreement to acquire Aderum Biotechnologies and its leading candidate Ixo-vec. 1 ...